Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An extension study of the patients enrolled in Acute Graft Versus Host Disease (GVHD) prophylaxis study (protocol no. FJ-506E-BT01) to assess safety and efficacy of GVHD prophylaxis of a tacrolimus new oral formulation (MR4).

Trial Profile

An extension study of the patients enrolled in Acute Graft Versus Host Disease (GVHD) prophylaxis study (protocol no. FJ-506E-BT01) to assess safety and efficacy of GVHD prophylaxis of a tacrolimus new oral formulation (MR4).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2006

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 27 Sep 2006 Status change
    • 05 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top